Redwood Pharma AB (REDW) Stock Overview

Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.